Induction of MAGE‐A3 and HPV‐16 immunity by Trojan vaccines in patients with head and neck carcinoma
CJ Voskens, D Sewell, R Hertzano, J DeSanto… - Head & …, 2012 - Wiley Online Library
Head & neck, 2012•Wiley Online Library
Background We performed a pilot study using Trojan vaccines in patients with advanced
squamous cell carcinoma of the head and neck (SCCHN). These vaccines are composed of
HLA‐I and HLA‐II restricted melanoma antigen E (MAGE)‐A3 or human papillomavirus
(HPV)‐16 derived peptides, joined by furin‐cleavable linkers, and linked to a “penetrin”
peptide sequence derived from HIV‐TAT. Thirty‐one patients with SCCHN were screened
for the trial and 5 were enrolled. Methods Enrolled patients were treated with 300 μg of …
squamous cell carcinoma of the head and neck (SCCHN). These vaccines are composed of
HLA‐I and HLA‐II restricted melanoma antigen E (MAGE)‐A3 or human papillomavirus
(HPV)‐16 derived peptides, joined by furin‐cleavable linkers, and linked to a “penetrin”
peptide sequence derived from HIV‐TAT. Thirty‐one patients with SCCHN were screened
for the trial and 5 were enrolled. Methods Enrolled patients were treated with 300 μg of …
Background
We performed a pilot study using Trojan vaccines in patients with advanced squamous cell carcinoma of the head and neck (SCCHN). These vaccines are composed of HLA‐I and HLA‐II restricted melanoma antigen E (MAGE)‐A3 or human papillomavirus (HPV)‐16 derived peptides, joined by furin‐cleavable linkers, and linked to a “penetrin” peptide sequence derived from HIV‐TAT. Thirty‐one patients with SCCHN were screened for the trial and 5 were enrolled.
Methods
Enrolled patients were treated with 300 μg of Trojan peptide supplemented with Montanide and granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) at 4‐week intervals for up to 4 injections.
Results
Following vaccination, peripheral blood mononuclear cells (PBMCs) from 4 of 5 patients recognized both the full Trojan constructs and constituent HLA‐II peptides, whereas responses to HLA‐I restricted peptides were less pronounced.
Conclusion
This treatment regimen seems to have acceptable toxicity and elicits measurable systemic immune responses against HLA‐II restricted epitopes in a subset of patients with advanced SCCHN. © 2012 Wiley Periodicals, Inc. Head Neck, 2012
Wiley Online Library以上显示的是最相近的搜索结果。 查看全部搜索结果